

H1
cond
of transforming growth factor consisting essentially of TGF- β_3
sufficient to effect said inhibition.

H2
64. (Amended) A method of reducing scarring during healing
of a wound in a patient in need thereof comprising providing at
the site of said wound an amount of transforming growth factor
consisting essentially of TGF- β_3 sufficient to effect said
reduction in scarring.

REMARKS

Reconsideration of this application and entry of the
foregoing amendments are respectfully requested.

The claims have been revised to define the invention with
additional clarity. Support for the revisions can be found
throughout the disclosure. That the claims have been revised
should not be construed as an indication that Applicants agree
with any view expressed by the Examiner. Rather the revisions
are made merely to advance prosecution.

In item (3) of the Action, the Examiner refers to "[a]
distinguishing property of TGF- β_3 is its disclosed ability to
induce non-fibrotic growth factor". Respectfully, it is believed
the Examiner intended to refer to induction of non-fibrotic
growth. Applicants point this out merely so that the record will
be clear.